Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOVNASDAQ:LMATNASDAQ:NVCROTCMKTS:WEDXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$33.05-0.1%$35.27$29.32▼$53.84$1.89B1.79767,722 shs1.75 million shsLMATLeMaitre Vascular$80.20-1.6%$84.15$71.42▼$109.58$1.81B0.86162,978 shs209,089 shsNVCRNovoCure$17.38-0.3%$17.92$14.17▼$34.13$1.94B0.731.17 million shs1.00 million shsWEDXFWestaim$23.690.0%$21.96$16.62▼$25.98$506.07M0.248,256 shs1,777 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis-3.10%-4.21%+8.20%-24.91%-34.51%LMATLeMaitre Vascular-0.16%-9.69%+4.63%-16.83%+8.67%NVCRNovoCure+4.83%-2.76%+13.56%-21.56%+8.88%WEDXFWestaim-0.21%+5.01%+14.88%+3.45%+731.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOVEnovis2.7565 of 5 stars3.41.00.00.03.21.71.9LMATLeMaitre Vascular2.9277 of 5 stars2.31.03.30.03.23.31.3NVCRNovoCure3.7961 of 5 stars3.33.00.04.52.41.70.0WEDXFWestaim0.5525 of 5 stars0.03.00.00.00.00.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.75Moderate Buy$55.0066.41% UpsideLMATLeMaitre Vascular 2.63Moderate Buy$98.1422.37% UpsideNVCRNovoCure 2.67Moderate Buy$32.8388.91% UpsideWEDXFWestaim 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest WEDXF, ENOV, NVCR, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ENOVEnovisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.005/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $57.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/10/2025NVCRNovoCureJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $28.004/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.004/2/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.002/28/2025LMATLeMaitre VascularLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$105.00 ➝ $110.002/28/2025LMATLeMaitre VascularOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/28/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/27/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$65.00 ➝ $64.00(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.11B0.90$4.82 per share6.86$62.66 per share0.53LMATLeMaitre Vascular$226.26M8.01$1.42 per share56.52$13.38 per share5.99NVCRNovoCure$621.71M3.12N/AN/A$3.39 per share5.13WEDXFWestaim$8.63M58.64$9.01 per share2.63$23.72 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$33.26M-$14.29N/A10.36N/A-5.95%4.39%2.80%N/ALMATLeMaitre Vascular$30.10M$1.9843.8336.962.2219.40%13.15%11.47%N/ANVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)WEDXFWestaim$183.98M-$0.8113.62∞N/A284.74%7.76%7.29%5/13/2025 (Estimated)Latest WEDXF, ENOV, NVCR, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million3/26/2025Q4 2024WEDXFWestaim$0.0618-$0.99-$1.0518-$0.99$4.70 million$4.60 million2/27/2025Q4 2024LMATLeMaitre Vascular$0.49$0.49N/A$0.49$55.99 million$55.81 million2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 million2/26/2025Q4 2024ENOVEnovis$0.92$0.98+$0.06-$12.05$555.14 million$560.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.801.00%+13.30%40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/AWEDXFWestaim$0.090.38%N/AN/A N/ALatest WEDXF, ENOV, NVCR, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/20252/18/2025LMATLeMaitre Vascularquarterly$0.200.9%3/13/20253/13/20253/27/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.402.271.12LMATLeMaitre VascularN/A7.745.52NVCRNovoCure0.271.491.44WEDXFWestaimN/A11.8111.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%WEDXFWestaimN/AInsider OwnershipCompanyInsider OwnershipENOVEnovis2.70%LMATLeMaitre Vascular10.79%NVCRNovoCure6.29%WEDXFWestaim4.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis6,80057.11 million55.49 millionOptionableLMATLeMaitre Vascular49022.59 million20.06 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableWEDXFWestaim721.36 million20.46 millionNot OptionableWEDXF, ENOV, NVCR, and LMAT HeadlinesRecent News About These CompaniesWestaim (OTCMKTS:WEDXF) Trading Up 4.1% - Here's What HappenedMay 8 at 3:55 AM | americanbankingnews.comWestaim (OTCMKTS:WEDXF) versus DIH Holding US (NASDAQ:DHAI) Head-To-Head ReviewMay 8 at 1:25 AM | americanbankingnews.comShort Interest in The Westaim Co. (OTCMKTS:WEDXF) Expands By 128.6%April 30, 2025 | marketbeat.comThe Westaim Co. (OTCMKTS:WEDXF) Short Interest Up 128.6% in AprilApril 29, 2025 | americanbankingnews.comThe Westaim Co. (OTCMKTS:WEDXF) Sees Large Increase in Short InterestApril 18, 2025 | marketbeat.comCC Capital and Westaim Complete Transaction, Creating Integrated Insurance and Asset Management PlatformApril 3, 2025 | businesswire.comWestaim Announces Receipt of Required Regulatory Approvals in Connection with CC Capital TransactionMarch 27, 2025 | businesswire.comThe Westaim Corporation Announces Normal Course Issuer BidMarch 26, 2025 | businesswire.comThe Westaim Corporation Reports Q4 and Full Year 2024 Results and Update on Timing of Proposed Transactions with CC CapitalMarch 26, 2025 | businesswire.comWestaim completes acquisition of ManhattanLifeFebruary 6, 2025 | insurancebusinessmag.comWestaim: Transforming Into A Potential Long-Term Compounding MachineJanuary 30, 2025 | seekingalpha.comThe Westaim Corp WEDXDJanuary 15, 2025 | morningstar.comThe Westaim Corporation Announces Completion of ArrangementJanuary 2, 2025 | businesswire.comWestaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)December 22, 2024 | theglobeandmail.comThe Westaim Corporation appoints CRODecember 6, 2024 | complianceweek.comThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comCC Capital & Westaim partner on new integrated insurance and asset management platformOctober 11, 2024 | reinsurancene.wsCC Capital and Westaim to create insurance and asset management platformOctober 9, 2024 | pehub.comWestaim Corporation: A Bargain In The Asset Management WorldSeptember 4, 2024 | seekingalpha.comWestaim Corporation: Still Undervalued Based On NAVJuly 19, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitChurchill Downs Stock: Could Tariff Fears Dampen Derby Gains?By Chris Markoch | April 26, 2025View Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?WEDXF, ENOV, NVCR, and LMAT Company DescriptionsEnovis NYSE:ENOV$33.05 -0.03 (-0.09%) As of 03:59 PM EasternEnovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LeMaitre Vascular NASDAQ:LMAT$80.20 -1.30 (-1.60%) As of 03:52 PM EasternLeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$17.38 -0.06 (-0.34%) As of 04:00 PM EasternNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Westaim OTCMKTS:WEDXF$23.69 -0.01 (-0.04%) As of 10:44 AM EasternThe Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Why Flutter Entertainment May Be a Resilient Sports Betting Stock OXY Stock Rebound Begins Following Solid Earnings Beat Is Energy Transfer Undervalued or a Value Trap? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
